Picture the person who will run bioMérieux’s new vaginitis test. A medical assistant at an urgent care clinic, between rooming one patient and taking vitals on the next, loads a swab into a small instrument on the counter and comes back about twenty minutes later to eight results. On October 22, bioMérieux announced that the FDA had granted the BIOFIRE SPOTFIRE Vaginitis Panel a dual 510(k) clearance and CLIA waiver. The waiver is what lets someone with little or no lab training run the test, and the FDA’s study rules for earning one push the choice of that operator back into design.
What a CLIA waiver certifies
A 510(k) clearance says a test is substantially equivalent to one already on the market. A CLIA waiver makes a different claim: the test is simple enough, with an insignificant risk of a wrong answer, to be run outside a laboratory by people with little or no lab training. bioMérieux’s own footnote says the waiver allows the panel to be used by non-lab professionals at the point of care.
The FDA’s guidance on the dual pathway, finalized in February 2020, spells out how you prove that. Studies should run at sites like the ones where the test will be used, on patients like the ones it is meant for, with operators who have the least training you’d expect to find there. The guidance also asks that testing fit into the daily workflow of a site where operators are juggling patient care, testing and other duties. One set of comparison and reproducibility studies run with those operators can serve both submissions, and the FDA calls the dual pathway, in many instances, the least burdensome and fastest route to a waiver.
The operator is a design input
Each of those study conditions sets a requirement for the product. The operator the guidance describes has little or no lab training, which caps how many steps they can be asked to touch. They are multitasking, so a patient may interrupt them halfway through and the run has to survive the pause. They read the result between tasks, so the display can’t leave room for a wrong reading. Those requirements land in the instrument, the cartridge and the software, and they have to be made before the clinical study starts, because the study takes place in that clinic with that person. bioMérieux widened the circle further: the panel accepts self-collected swabs as well as clinician-collected ones, so the sample itself may come from a patient with no training at all.
I put the choice of operator with whoever owns the product, and I want it made while the design can still change around it. A test designed for a trained lab technologist and taken to a waiver later has to show the same performance in the hands of someone with far less training, in a busy clinic, and its design may never have been built to allow that.
What bioMérieux already had
bioMérieux made that choice at the platform level, before this panel existed. It describes SpotFire as a small, modular instrument designed to fit in any healthcare setting, including family practices, urgent care and OB/GYN offices, and the system already runs respiratory and sore throat panels. The vaginitis panel is a new test for an operator the platform was built around from the start, which is an advantage a startup filing its first waived test doesn’t have. The dual submission went in on June 26 and the decision was announced on October 22, a little under four months later. bioMérieux says the panel goes on sale in the US at the start of 2027.
Who runs it on a bad day
Before a first architecture review, I want a job title for the person who will run the product on a bad day, and a list of what else they will be doing when it happens. For a waived test like bioMérieux’s it might be a medical assistant with patients waiting. On a factory floor it might be a second-shift operator who never met the integrator who installed the robot cell, and in a home, a patient reading the screen without their glasses. Each is that product’s version of the least-trained operator the FDA asks waiver studies to recruit.
Dave’s take
The operator a CLIA waiver certifies gets chosen in design, long before anyone writes the filing. When I run product for a hardware team, the job title of that least-trained operator is one of the first things I want written into the requirements, because the study protocol and the label will both have to agree with it.
From Dave’s video library
Dave on why the commercial questions, who buys a product and who uses it, have to be answered before the engineering starts.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour working session →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →